According to the report titled ‘U.S. Non-Invasive Prenatal Testing Market Research and Outlook, 2021 - Trends, Growth Opportunities, Competitive Analysis and Forecasts to 2028’ available with MarketStudyReport, the United States non-invasive prenatal testing (NIPT) market is predicted to be worth USD 2.5 billion by the year 2028.

The U.S. non-invasive prenatal testing (NIPT) market size is expanding due to growing per capita income, higher incidence of chromosomal aneuploidies among fetuses, and an improvement in consumer cognizance. Also, emergence of advanced non-invasive prenatal testing products, emphasis on reimbursement for NIPT, and increasing preference for non-invasive techniques over invasive ones are positively swaying the industry dynamics.

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/3950419/

Notably, ACOG (American College of Obstetricians and Gynecologists) guidelines recommend NIPT for all pregnancies, which is likely to act in favor of the market scenario.

This report provides a complete analysis of the non-invasive prenatal testing industry in the U.S. and helps the readers with the most up-to-date data on the current conditions and forecasts for growth rate and valuation over 2021-2028. It also includes extensive historical information from 2015 to 2020, as well as an indicative projection to 2028, covering major market parameters such as market value and volume.

Speaking of the competitive landscape, the top players in the U.S. non-invasive prenatal testing (NIPT) market include companies like Integrated Genetics, Progenity, Illumina Inc., Centogene AG, Ariosa Diagnostics Inc., Natera Inc., PerkinElmer Inc., Quest Diagnostics, Agilent Technologies Inc., GenPath Oncology, Myriad Genetics, Invitae Corporation, and Yourgene Health PLC among others.